Hinge Health, Inc. (HNGE) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Hinge Health, Inc. is a digital health company focused on scaling and automating the delivery of musculoskeletal (MSK) care through an AI-powered platform, wearable devices (Enso), and a network of licensed clinicians. The company primarily serves self-insured employers, health plans, and Medicare Advantage populations. As of March 31, 2026, the company reported 2,849 clients and 782,890 members.
Key Financial Metrics
| Metric (in thousands, except per share) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $182,307 | $123,825 |
| Gross Profit | $154,233 | $100,233 |
| Gross Margin | 85% | 81% |
| Operating Income | $32,069 | $13,137 |
| Net Income | $35,128 | $17,139 |
| Diluted EPS | $0.41 | $1.31 |
| Operating Cash Flow | $43,083 | $4,925 |
| Free Cash Flow | $41,553 | $4,168 |
| Cash & Marketable Securities | $405,667 | $N/A |
Note: Q1 2025 EPS was significantly impacted by a one-time $104.2 million deemed contribution from preferred stock extinguishment.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 47% year-over-year to $182.3 million, driven primarily by growth from existing clients and higher member engagement.
- Profitability: The company achieved GAAP net income of $35.1 million, compared to $17.1 million in Q1 2025. Operating margin improved to 18% from 11%.
- Expense Increases: Operating expenses rose 47% to $122.2 million. Sales and marketing expenses increased 47% (driven by commissions and marketing costs), and R&D expenses increased 29% (driven by stock-based compensation and professional services).
- Cash Flow: Operating cash flow surged to $43.1 million from $4.9 million, aided by a $39.9 million increase in deferred revenue.
- Share Repurchases: The company repurchased 2.45 million shares of Class A common stock for $105.8 million during the quarter under a $250 million program authorized in November 2025.
Guidance, Outlook, and Risks
Management Commentary: Management highlighted the scalability of their AI-powered model, which reduced human care team hours by approximately 97% compared to traditional physical therapy. The company continues to expand into fully-insured and Medicare Advantage markets and launched "HingeSelect," a high-performance in-person provider network, in 2025.
Key Risks and Contingencies:
- Regulatory Environment: Significant risks exist regarding FDA regulation of the Enso device and AI-powered software (TrueMotion). The FDA requested information regarding TrueMotion in April 2025; the company believes it is not a medical device but faces uncertainty.
- Partner Concentration: A substantial portion of revenue (84% in Q1 2026) comes through a limited number of health plan partners. The top three partners (HCSC, Elevance, Aetna) accounted for over 39% of revenue.
- AI and Data Privacy: Increasing reliance on AI introduces risks related to data accuracy, regulatory compliance (e.g., EU AI Act, state-level AI laws), and potential liability.
- Capital Structure: The company has a dual-class structure where Class B shares (held by founders) and Series E preferred stock (held by Tiger Global) hold significant voting control (15 votes per share).
Investor Verification Checklist
- Partner Dependency: Verify the stability of contracts with top three health plan partners (HCSC, Elevance, Aetna) which drive nearly 40% of revenue.
- Regulatory Status of AI: Monitor the outcome of the FDA inquiry regarding the TrueMotion AI technology and potential reclassification as a medical device.
- Share Repurchase Impact: Assess the remaining $80 million authorization under the share repurchase program and its impact on future liquidity.
- Preferred Stock Rights: Review the liquidation preferences and voting rights of the outstanding Series E preferred stock ($200 million liquidation preference).
- Seasonality: Confirm if Q1 results align with historical seasonality patterns where billings are typically lower in Q1 due to client launch timing.